
Oral menopausal hormone therapy causes venous thrombosis but whether biomarkers of thrombosis risk can identify women at risk is unknown.
Oral menopausal hormone therapy causes venous thrombosis but whether biomarkers of thrombosis risk can identify women at risk is unknown.
Celebrating outstanding practice across healthcare services involved in the management and care of anticoagulation therapy, applications are now invited for the 2018 Anticoagulation Achievement Awards.
Thrombosis UK are very concerned to learn that the Scottish clinical guidance for VTE – SIGN Guidance 122, first published 2010 and then updated in 2014, may be withdrawn in 2020